|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.39 USD | +5.38% |
|
+2.82% | +37.34% |
| May. 09 | Wedbush Raises Price Target on Revolution Medicines to $46 From $42, Maintains Outperform Rating | MT |
| May. 08 | Revolution Medicines Q1 Net Loss Narrows | MT |
Revolution Medicines, Inc. provided earnings guidance for the full year 2022. For the period, the company projected GAAP net loss to be between $260 million and $280 million.
| 1st Jan change | Capi. | |
|---|---|---|
| +37.34% | 6.5B | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.39% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
REVOLUTION MEDICINES, INC. 
